MG
MGX.US Metagenomi, Inc. Common Stock
- Market cap
- USD 26.2M
- P/E
- -
- P/B
- 0.28x
- ROE
- -101.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2026.
Is MGX.US undervalued?
Graham numberThe Graham number of Metagenomi, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Metagenomi, Inc. Common Stock fundamental analysis
No fundamental analysis for Metagenomi, Inc. Common Stock yet.
Metagenomi, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin am…
Full company profileMetagenomi, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 4 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Metagenomi, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 243K | 17.2M | 44.8M | 52.3M | 25.2M | 7.09M |
| Gross Profit | -144K | 15.5M | -49.6M | 52.3M | 19.9M | 4.92M |
| Operating Income | -23.9M | -44.6M | -78.5M | -88.9M | -96.0M | -100.0M |
| EBITDA | -20.8M | -39.2M | -56.0M | -78.2M | -82.6M | -90.3M |
| Net Income | -21.4M | -43.6M | -68.3M | -78.1M | -87.9M | -94.2M |
| EPS | -3.62 | -1.16 | -1.82 | -2.09 | -2.36 | -2.49 |
| Balance Sheet | ||||||
| Total Assets | 142M | 414M | 365M | 325M | 221M | 157M |
| Total Liabilities | 175M | 489M | 500M | 89.7M | 62.5M | 64.2M |
| Shareholders' Equity | -32.5M | -74.4M | -136M | 235M | 159M | 93.2M |
| Cash & Short-term Investments | 108M | 362M | 271M | 248M | 161M | 102M |
| Total Debt | 48.9M | 18.6M | 48.2M | 45.8M | 40.7M | 36.2M |
| Cash Flow | ||||||
| Operating Cash Flow | 24.3M | 29.7M | -91.4M | -109M | -88.9M | -83.3M |
| Capital Expenditure | 2.90M | 14.0M | 9.81M | 3.11M | 574K | 256K |
| Free Cash Flow | 21.4M | 15.7M | -101M | -112M | -89.5M | -83.5M |
| Ratios | ||||||
| ROE | - | - | - | -33.2% | -55.4% | -101.1% |
| ROA | -15.1% | -10.5% | -18.7% | -24.0% | -39.7% | -59.8% |
| Net Profit Margin | -8,823.9% | -253.4% | -152.5% | -149.3% | -348.5% | -1,329.3% |
| Debt to Equity | - | - | - | 0.19x | 0.26x | 0.39x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Metagenomi, Inc. Common Stock dividends
Metagenomi, Inc. Common Stock has not paid dividends in the last 5 fiscal years.
Who owns Metagenomi, Inc. Common Stock
- Insiders 19.04%
- Institutions 18.20%
- Public & others 62.76%
- Shares outstanding 37.8M
- Free float 25.6M
Top funds holding MGX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 741K | 1.96% | 0.00% | Sep 2026 |
| Bridgeway Ultra-Small Company | 327K | 0.87% | 0.00% | Jun 2026 |
| Fidelity Extended Market Index | 135K | 0.36% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 86.7K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 47.2K | 0.13% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 37.2K | 0.10% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 36.1K | 0.10% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 20.8K | 0.06% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 13.4K | 0.04% | 0.00% | Sep 2026 |
| Dimensional World Equity GBP Acc | 7.91K | 0.02% | -0.21% | Sep 2026 |
| 1290 VT Micro Cap K | 6.88K | 0.02% | 0.00% | Sep 2026 |
| Dimensional Global Small Coms USD Acc | 4.86K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding MGX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 1.08M | 2.85% | +1.87% | Jun 2026 |
| Renaissance Technologies Corp | 624K | 1.65% | -15.91% | Sep 2026 |
| Catalio Capital Management, LP | 529K | 1.40% | 0.00% | Jun 2026 |
| Peapod Lane Capital LLC | 525K | 1.39% | +1.60% | Jun 2026 |
| Two Sigma Investments LLC | 514K | 1.36% | +3.41% | Jun 2026 |
| Bridgeway Capital Management, LLC | 400K | 1.06% | +1.14% | Jun 2026 |
| Wells Fargo & Co | 380K | 1.00% | +87.75% | Jun 2026 |
| Geode Capital Management, LLC | 289K | 0.76% | -19.41% | Jun 2026 |
| PURA VIDA INVESTMENTS, LLC | 264K | 0.70% | 0.00% | Jun 2026 |
| BlackRock Inc | 258K | 0.68% | +11.95% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 171K | 0.45% | +0.63% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 160K | 0.42% | -58.13% | Jun 2026 |
| State Street Corp | 120K | 0.32% | -0.48% | Jun 2026 |
| Millennium Management LLC | 114K | 0.30% | -32.97% | Jun 2026 |
| Man Group PLC | 109K | 0.29% | +38.78% | Jun 2026 |
| Resolute Advisors LLC | 89.9K | 0.24% | 0.00% | Jun 2026 |
| Marquette Asset Management Inc. | 72.1K | 0.19% | 0.00% | Jun 2026 |
| Northern Trust Corp | 68.9K | 0.18% | -8.29% | Jun 2026 |
| RBF LLC | 64.0K | 0.17% | 0.00% | Sep 2026 |
| XTX Topco Ltd | 55.7K | 0.15% | +37.27% | Jun 2026 |
Metagenomi, Inc. Common Stock company profile
- Company name
- Metagenomi, Inc. Common Stock
- Ticker
- MGX.US
- Exchange
- USA Stocks
- Listed since
- Feb 9, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 119
- Fiscal year end
- September
- Address
- 5959 Horton Street, EmeryVille, CA, United States, 94608
- Phone
- 510 871 4880
- Website
- metagenomi.co
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Metagenomi, Inc. Common Stock management
8- Dr. Jian Irish M.B.A., Ph.D.CEO, President & Director · born 1964
- Ms. Pamela M. Wapnick M.B.A.Chief Financial Officer · born 1966
- Mr. Matthew L. Wein J.D.General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary · born 1971
- Dr. Joseph Knowles M.D.Co-Founder & Member of Scientific Advisory Board
- Mr. Mark LeonardSenior Vice President of Technical Development & Operations
- Dr. Alan Brooks Ph.D.Senior Vice President of Research · born 1966
- Ms. Katalin Kauser M.D., Ph.D.Senior Vice President of Translational Biology
- Mr. Nikhil Bhide M.B.A.Senior Vice President of Business Development